Lansoprazole versus ranitidine in the maintenance treatment of reflux oesophagitis

Authors


  • The following clinicians also contributed to this study: Professor G. Barbezat, Dunedin, New Zealand; Dr K.D. Bardhan, Rotherham District General Hospital, Rotherham, UK; Dr D. Colin Jones, Queen Alexandra Hospital, Portsmouth, UK; Dr P Davies, E Glamorgan Hospital, Pontypridd, UK; Dr M.W. Dronfield, Peterborough District Hospital, Peterborough, UK; Dr D. Foster, Birch Hill Hospital, Rochdale, UK; Dr A.E. Gent, Salisbury General Hospital, Salisbury, UK; Dr I. Hamilton, University of Auckland, New Zealand; Dr R. Holden, Monklands District General Hospital, Airdrie, UK; Dr S.P. Kane, West Middlesex Hospital, Twickenham, UK; Dr C. Loehry, Bournemouth General Hospital, Bournemouth, UK; Dr A.P. Manning, Bradford Royal Infirmary, Bradford, UK; Dr J. Mayberry, Leicester General Hospital, Leicester, UK; Dr P. Mills, Gartnavel General Hospital, Glasgow, UK; Dr G. Neale, Addenbrooke's Hospital, Cambridge, UK; Dr A. Tanner, North Tees General Hospital, Stockton-on Tees, UK; Mr C. Venables, Freeman Hospital, Newcastle-upon Tyne, UK; Dr C.P. WIlloughby, Basildon General Hospital, Basildon, UK. We would like to thank Sue Huxtable and Stephanie Trevor for data processing. This study was sponsored by Lederle Laboratories, Gosport, UK.

Mr A. L. Gough Weston General Hospital, Grange Road, Weston-super-Mare, Avon BS23 4TQ, UK.

Abstract

Aims: To assess the relative efficacies of lansoprazole 15 mg once daily, lansoprazole 30 mg once daily and ranitidine 300 mg b.d. in the maintenance treatment of reflux oesophagitis for 12 months.

Methods: Multicentre, out-patient, double-blind, parallel group, prospectively randomized clinical trial. Patients with grade 0, asymptomatic oesophagitis after 8 weeks of treatment with lansoprazole 30 mg once daily were randomized to receive lansoprazole 30 mg once daily (L30) (n=75), lansoprazole 15 mg once daily (L15) (n=86) or ranitidine 300 mg b.d. (R600) (n=74) for 12 months. Endoscopy was repeated at 6 and 12 months, and symptomatic assessment was made every 3 months. Efficacy was primarily assessed by the time to endoscopically confirmed relapse (oesophagitis gradegeqslant R: gt-or-equal, slanted1) and the proportion of patients who relapsed during the 12-month study period. Severity of symptoms were secondary efficacy measures.

Results: For all patients randomized with at least one post-baseline endoscopy (intent-to-treat principle) both lansoprazole 15 mg (P<0.001) and lansoprazole 30 mg (P<0.001) were significantly superior to ranitidine 600 mg with respect to time to endoscopic relapse. There was no difference between the lansoprazole groups (P=0.11). There was evidence of relapse in 27 of 86 (31.4%), 15 of 75 (20.0%) and 50 of 74 (67.6%) of the patients treated with lansoprazole 15 mg and 30 mg and ranitidine 600 mg, respectively. Patients receiving treatment with either lansoprazole dosages experienced significantly less severe heartburn and regurgitation than those patients treated with ranitidine. There were no differences between the treatment groups with respect to the severity or incidence of adverse events. No clinically significant laboratory changes were observed in any of the treatment groups. Serum gastrin levels were elevated in all treatment groups, and most markedly in those patients receiving lansoprazole, but there was no significant difference between the treatments. Morphological and immunohistochemical examination of the gastric biopsies revealed no clinically relevant changes from baseline in any of the treatment groups.

Conclusion: Both lansoprazole 15 mg and lansoprazole 30 mg once daily are significantly more effective than high-dose ranitidine in maintaining reflux oesophagitis in remission.

Ancillary